5.695
7.66%
+0.405
Foghorn Therapeutics Inc Aktie (FHTX) Neueste Nachrichten
How To Trade (FHTX) - Stock Traders Daily
Stock Traders Daily
Foghorn Therapeutics Inc. (FHTX) Soars 13.1%: Is Further Upside Left in the Stock? - Yahoo Lifestyle UK
Yahoo Lifestyle UK
Foghorn Therapeutics Inc. (NASDAQ:FHTX) insider upped their holding by 2.2% earlier this year - Yahoo News UK
Yahoo News UK
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target - Simply Wall St
Simply Wall St
Strength Seen in Foghorn Therapeutics Inc. (FHTX): Can Its 5.3% Jump Turn into More Strength? - Yahoo Movies UK
Yahoo Movies UK
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target - Yahoo Finance
Yahoo Finance
Foghorn Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Yahoo Finance
(FHTX) Technical Data - Stock Traders Daily
Stock Traders Daily
Foghorn Therapeutics Q1 2024 Earnings: Misses Analyst Revenue Projections Amidst Strategic ... - Yahoo Finance
Yahoo Finance
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Yahoo Finance
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update - Yahoo Finance
Yahoo Finance
Can Foghorn Therapeutics Inc. (FHTX) Climb 161% to Reach the Level Wall Street Analysts Expect? - Yahoo Movies Canada
Yahoo Movies Canada
Foghorn Therapeutics (NASDAQ:FHTX) Stock Rating Reaffirmed by HC Wainwright - Defense World
Defense World
Foghorn Therapeutics (NASDAQ:FHTX) Earns Buy Rating from HC Wainwright - MarketBeat
MarketBeat
Petri Dish: Non-viral vector startup launch; Foghorn's new CFO - Boston Business Journal - The Business Journals
The Business Journals
Foghorn Therapeutics Appoints Kristian Humer as New CFO - TipRanks.com - TipRanks
TipRanks
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer - Yahoo Finance
Yahoo Finance
Companies Like Foghorn Therapeutics (NASDAQ:FHTX) Are In A Position To Invest In Growth - Simply Wall St
Simply Wall St
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
GlobeNewswire Inc.
Foghorn Therapeutics Unveils Cancer Research Breakthroughs - TipRanks.com - TipRanks
TipRanks
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
GlobeNewswire Inc.
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 105.75% as Wall Street Analysts Expect?
Zacks Investment Research
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
GlobeNewswire Inc.
Have Insiders Sold Foghorn Therapeutics Shares Recently? - Simply Wall St
Simply Wall St
Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's What You Should Know
Zacks Investment Research
Wall Street Analysts Predict a 124.31% Upside in Foghorn Therapeutics Inc. (FHTX): Here's What You Should Know
Zacks Investment Research
Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Yahoo Finance
Cambridge biotech discloses it quietly reduced staff by 28% last year - Boston Business Journal - The Business Journals
The Business Journals
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook - GlobeNewswire
GlobeNewswire
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with ... - GlobeNewswire
GlobeNewswire
Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock?
Zacks Investment Research
VRTX: Dominate the Market With 3 Biotech Stocks - StockNews.com
StockNews.com
Foghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last? - Yahoo Finance
Yahoo Finance
Foghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last?
Zacks Investment Research
Foghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 Development
Zacks Investment Research
Lilly selects BRM-selective inhibitor for clinical development - BioWorld Online
BioWorld Online
FHTX Stock Quote Price and Forecast - CNN
CNN
Foghorn Shares Rally as Eli Lilly Plans Clinical Program With Oncology Product - MarketWatch
MarketWatch
GILD: 3 Biotech Stock Gems Bursting With Buy Opportunities - StockNews.com
StockNews.com
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) latest 20% decline adds to one-year losses, institutional investors may consider drastic measures - Simply Wall St
Simply Wall St
Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's Why
Zacks Investment Research
How Much Upside is Left in Foghorn Therapeutics Inc. (FHTX)? Wall Street Analysts Think 160.57%
Zacks Investment Research
Foghorn Therapeutics discovers new SMARCA2 and SMARCA4 degradation inducers - BioWorld Online
BioWorld Online
Foghorn Therapeutics Names Quintás-Cardama Chief Medical Officer - Contract Pharma
Contract Pharma
Foghorn Therapeutics doses first patient in AML therapy trial - Clinical Trials Arena
Clinical Trials Arena
Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update - Yahoo Finance
Yahoo Finance
Foghorn downgraded to full clinical hold, with more patient deaths clouding AML, MDS trial - Fierce Biotech
Fierce Biotech
Foghorn Therapeutics to Participate at the 2022 Guggenheim Targeted Protein Degradation Day - Yahoo Finance
Yahoo Finance
How Eli Lilly's potential ~$1.7B partnership with Foghorn bolsters its oncology portfolio - Seeking Alpha
Seeking Alpha
Kapitalisierung:
|
Volumen (24h):